As lawyers who represent whistleblowers under the False Claims Act, we expect a new era of fraud cases tied to GLP-1 drugs, ...

Medicare covers weight loss drugs including Ozempic under specific conditions when the drug also has potential use cases beyond weight loss.

Medicare and Medicaid could expand coverage of GLP-1 drugs, such as Ozempic and Wegovy, and pay for patients’ use of the ...

The federal government is expected to start a 5-year-long experiment that will provide some limited coverage of obesity ...

A five-year experiment aims to open access to blockbuster GLP‑1 drugs for obesity, something advocates have pushed for years.

Investing.com - Barclays在有关计划中的Medicare GLP-1药物试点计划报道后，重申了对诺和诺德公司 (CSE:NOVOB) (NYSE: NVO )的"持平"评级和375.00丹麦克朗的目标价。 《华盛顿邮报》周五报道，美国卫生与公众服务部和医疗保险与医疗补助服务中心计划启动一项为期五年的试点计划，允许Medicare ...

数百万参加俗称“红蓝卡”联邦 医疗 保险（Medicare）或“白卡”联邦医疗补助（Medicaid）计划的肥胖症患者，可望透过川普政府推出为期五年的实验计划取得价格昂贵的减肥药物，例如胰妥赞（ Ozempic)。

Blockbuster weight loss drugs like Wegovy and Zepbound have surged in popularity, but high prices have left them out of reach for many obese Americans.

The Centers for Medicare & Medicaid Services (CMS) is developing a pilot program that could change the landscape of obesity ...

The Trump administration is planning a five-year test allowing states to cover weight-loss drugs like Ozempic and Wegovy ...

The Trump administration is exploring a five-year pilot program to include weight-loss drugs like Wegovy, Ozempic, Zepbound, ...

Ozempic may be adding some spring to your step — but it might also be taking a bite out of your smile. As the popularity of weight-loss drugs surges, a new concern is emerging: “Ozempic teeth.” ...